July 16, 2021 09:39 AM Eastern Daylight Time
This Smart Pharma report examines the integration of smart technologies across the pharmaceutical industry value chain, assesses COVID-19 impact on the uptake of smart technologies in pharma and importance of partnering with technology vendors to enable a roll-out of innovative technologies. The COVID-19 pandemic has given businesses an unprecedented opportunity to accelerate and implement technology-fueled changes to the way they operate. Even though digital transformation and smart technologies uptake had already begun pre-pandemic, COVID-19 made this process even more pressing. While in the past the pharmaceutical sector used to display a more conservative stance toward the adoption of new technologies, the COVID-19 pandemic was a major catalyst for the industry to rethink and redefine their operations and embrace digital transformation at a faster pace. For pharmaceutical companies, the pandemic forced many to rethink and readjust their drug development process, manufacturing, supply chains, marketing strategies, and end-customer reach. Although pharmaceutical companies mainly relied on technologies before the pandemic to enhance internal processes, now digital technologies are becoming necessary to ensure business continuity and to gain competitive edge. Scope
A total of 155 of the publisher's Pharma clients and prospects participated in the 10-minute survey, which was fielded from April 21, 2021 to May 18, 2021. In this report, smart pharma refers to the incorporation of new technologies to improve and enhance processes such as drug development, manufacturing, supply chains, and sales and marketing. Components of the report include:
Adoption of Smart Technologies in Pharma - highlights the main challenges and benefits associated with implementation of smart technologies within the pharmaceutical industry providing respondent mix by region, and company size. Drug Discovery and Development - assesses the smart technologies that are expected to play a major role in optimizing drug discovery and development process and highlights the current and future technologies uptake. Manufacturing - examines the smart technologies that are expected to play a major role in optimizing pharmaceutical manufacturing process and highlights the current and future technologies uptake. Supply Chains - evaluates the smart technologies that are expected to play a major role in optimizing supply chains and highlights the current and future technologies uptake. Sales and marketing - assesses the smart technologies that are expected to play a major role in optimizing sales and marketing process and highlights the current and future technologies uptake. Pharma and Tech Collaborations - showcases how pharmaceutical industry is partnering with external technology vendors to increase the implementation speed, efficiency, and reliability of new technologies. A Closer Look at Big Data and AI - highlights the importance of Artificial Intelligence and Big Data in pharmaceutical industry. COVID-19 Impact - assesses the COVID-19 impact on the acceleration of smart technologies uptake. Key Topics Covered:

Smart Pharma Thematic Research Report 2021: The Importance of Artificial Intelligence and Big Data - ResearchAndMarkets.com

Smart Pharma Thematic Research Report 2021: The Importance of Artificial Intelligence and Big Data - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Smart Pharma - Thematic Research" report has been added to ResearchAndMarkets.com's offering. This Smart Pharma report examines the integration of smart technologies across the pharmaceutical industry value chain, assesses COVID-19 impact on the uptake of smart technologies in pharma and importance of partnering with technology vendors to enable a roll-out of innovative technologies. The COVID-19 pandemic has given businesses an unprecedented opportunity to accelerate and implement technology-fueled changes to the way they operate. Even though digital transformation and smart technologies uptake had already begun pre-pandemic, COVID-19 made this process even more pressing. While in the past the pharmaceutical sector used to display a more conservative stance toward the adoption of new technologies, the COVID-19 pandemic was a major catalyst for the industry to rethink and redefine their operations and embrace digital transformation at a faster pace. For pharmaceutical companies, the pandemic forced many to rethink and readjust their drug development process, manufacturing, supply chains, marketing strategies, and end-customer reach. Although pharmaceutical companies mainly relied on technologies before the pandemic to enhance internal processes, now digital technologies are becoming necessary to ensure business continuity and to gain competitive edge. Scope
A total of 155 of the publisher's Pharma clients and prospects participated in the 10-minute survey, which was fielded from April 21, 2021 to May 18, 2021. In this report, smart pharma refers to the incorporation of new technologies to improve and enhance processes such as drug development, manufacturing, supply chains, and sales and marketing. Components of the report include:
Adoption of Smart Technologies in Pharma - highlights the main challenges and benefits associated with implementation of smart technologies within the pharmaceutical industry providing respondent mix by region, and company size. Drug Discovery and Development - assesses the smart technologies that are expected to play a major role in optimizing drug discovery and development process and highlights the current and future technologies uptake. Manufacturing - examines the smart technologies that are expected to play a major role in optimizing pharmaceutical manufacturing process and highlights the current and future technologies uptake. Supply Chains - evaluates the smart technologies that are expected to play a major role in optimizing supply chains and highlights the current and future technologies uptake. Sales and marketing - assesses the smart technologies that are expected to play a major role in optimizing sales and marketing process and highlights the current and future technologies uptake. Pharma and Tech Collaborations - showcases how pharmaceutical industry is partnering with external technology vendors to increase the implementation speed, efficiency, and reliability of new technologies. A Closer Look at Big Data and AI - highlights the importance of Artificial Intelligence and Big Data in pharmaceutical industry. COVID-19 Impact - assesses the COVID-19 impact on the acceleration of smart technologies uptake. Key Topics Covered:

Search jobs
11-May-2021
BISTel Showcases Smart Pharma Innovation Award Winner GrandView APM at 2021 Manufacturing Assets and Reliability Conference
Designed for manufacturing, GrandView AI assures constant uptime, extends asset life, and increases knowledge sharing across the pharma manufacturing industry
SANTA CLARA, Calif.--(BUSINESS WIRE)-- #AI --BISTel, a leading provider of AI asset performance management (APM) solutions for industrial manufacturing, announced today that it will feature its AI based GrandView APM solution at the annual Manufacturing Assets and Reliability in Pharma 2021 Conference . Winner of the 2020 Pharma Manufacturing Magazine, Smart Pharma Innovation Award, GrandView APM was launched last year to help manufacturers achieve the vision of industry 4.0 by leveraging asset and factory data across the manufacturing ecosystem. The pharmaceutical industry is one of the early adopters of industry 4.0 technologies, deploying digital transformation technologies to help drive continuous improvements at factories worldwide. “Pharma is making progress in embracing Industry 4.0 and AI based predictive maintenance is one area where they can make a quick and significant impact on the production environment,” said WK Choi, CEO, BISTel. “We are pleased to sponsor the Manufacturing Assets in Pharma conference and to demonstrate our award-winning smart pharma solution.”
BISTel’s innovative asset data centric management approach helps pharma manufactures generate deeper insights at the asset level and across the entire production environment. This approach helps connect, analyze and share knowledge across the ecosystem, using this data to create insights that drive massive continuous improvements for a sector that is constantly looking for ways to improve efficiency and reduce overall production costs. About GrandView
At this week’s conference, the GrandView™ will show how it provides for continuous monitoring of the health and performance of factory equipment, pumps, motors, fans, and other manufacturing assets and showcase powerful data visualization for all users. Coupled with an asset health index and AI predictive analytics technology, pharma users can generate a RUL (remaining useful life) prediction, pinpointing when assets will fail. Users can also connect the GrandView APM prediction to their plant’s CMMS, EAM or ERP systems, automatically generating a work order to order parts and perform maintenance — thereby minimizing or even eliminating system downtime. In addition, GrandView is scalable and helps transition manufacturers seamlessly and cost effectively from legacy, inefficient scheduled based maintenance to AI predictive based maintenance approaches. This saves manufacturers millions of dollars in maintenance costs alone and extends the life of valuable equipment. About BISTel
For more than 20 years, BISTel’s AI based, intelligent manufacturing solutions collect and manage data, monitor the health of equipment, optimize process flows, analyze large data, quickly identify root cause failures to mitigate risk, predicting issues before they occur and extending the life of valuable equipment and other assets through industry leading manufacturing AI predictive analytics. BISTel helps customers reduce downtime, improve yield, increase asset utilization, achieving significant production and engineering efficiencies across the factory. Founded in 2000, BISTel has more than 395 employees worldwide. The company is headquartered in South Korea, with US Headquarters in Santa Clara California, and operations throughout China, France, Singapore and Texas. BISTel’s domain expertise in manufacturing AI, includes, auto, flat panel, industrial, petrochemicals, semiconductor as well as automotive, and pharmaceutical manufacturing. For more information visit bistel.com or www.grandview-apm.com
Contacts

BISTel Showcases Smart Pharma Innovation Award Winner GrandView APM at 2021 Manufacturing Assets and Reliability Conference

Intellasia East Asia News
12-May-2021 Intellasia |   |  1:54 AM
Designed for manufacturing, GrandView AI assures constant uptime, extends asset life, and increases knowledge sharing across the pharma manufacturing industry
SANTA CLARA, Calif.–(BUSINESS WIRE)– #AI –BISTel, a leading provider of AI asset performance management (APM) solutions for industrial manufacturing, announced today that it will feature its AI based GrandView APM solution at the annual Manufacturing Assets and Reliability in Pharma 2021 Conference . Winner of the 2020 Pharma Manufacturing Magazine, Smart Pharma Innovation Award, GrandView APM was launched last year to help manufacturers achieve the vision of industry 4.0 by leveraging asset and factory data across the manufacturing ecosystem. The pharmaceutical industry is one of the early adopters of industry 4.0 technologies, deploying digital transformation technologies to help drive continuous improvements at factories worldwide. “Pharma is making progress in embracing Industry 4.0 and AI based predictive maintenance is one area where they can make a quick and significant impact on the production environment,” said WK Choi, CEO, BISTel. “We are pleased to sponsor the Manufacturing Assets in Pharma conference and to demonstrate our award-winning smart pharma solution.”
BISTel’s innovative asset data centric management approach helps pharma manufactures generate deeper insights at the asset level and across the entire production environment. This approach helps connect, analyze and share knowledge across the ecosystem, using this data to create insights that drive massive continuous improvements for a sector that is constantly looking for ways to improve efficiency and reduce overall production costs. About GrandView
At this week’s conference, the GrandView™ will show how it provides for continuous monitoring of the health and performance of factory equipment, pumps, motors, fans, and other manufacturing assets and showcase powerful data visualization for all users. Coupled with an asset health index and AI predictive analytics technology, pharma users can generate a RUL (remaining useful life) prediction, pinpointing when assets will fail. Users can also connect the GrandView APM prediction to their plant’s CMMS, EAM or ERP systems, automatically generating a work order to order parts and perform maintenance — thereby minimizing or even eliminating system downtime. In addition, GrandView is scalable and helps transition manufacturers seamlessly and cost effectively from legacy, inefficient scheduled based maintenance to AI predictive based maintenance approaches. This saves manufacturers millions of dollars in maintenance costs alone and extends the life of valuable equipment. About BISTel
For more than 20 years, BISTel’s AI based, intelligent manufacturing solutions collect and manage data, monitor the health of equipment, optimize process flows, analyze large data, quickly identify root cause failures to mitigate risk, predicting issues before they occur and extending the life of valuable equipment and other assets through industry leading manufacturing AI predictive analytics. BISTel helps customers reduce downtime, improve yield, increase asset utilization, achieving significant production and engineering efficiencies across the factory. Founded in 2000, BISTel has more than 395 employees worldwide. The company is headquartered in South Korea, with US Headquarters in Santa Clara California, and operations throughout China, France, Singapore and Texas. BISTel’s domain expertise in manufacturing AI, includes, auto, flat panel, industrial, petrochemicals, semiconductor as well as automotive, and pharmaceutical manufacturing. For more information visit bistel.com or www.grandview-apm.com
Contacts

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Biopharma Tech

Acquired

Smart Pharma produces and sells drugs and medical products. The company also provides services to other companies in the industry. Smart Pharma's products include Innofer, Innofer Baby and Diflos (a probiotic containing strains of bacteria). On September 17th, 2020, Smart Pharma was acquired by Chiesi, terms of the transaction were not disclosed.

Wells Fargo Success Story

Professional Services

Platform Overview

Smart Pharma

Compete with Smart Pharma?

Compete with Smart Pharma?

Discover the right solution for your team